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Coccidial parasites cause medical and veterinary diseases worldwide, frequently leading
to severe illness and important economic losses. At present, drugs, chemotherapeutics
and prophylactic vaccines are still missing for most of the coccidial infections. Moreover,
the development and administration of drugs and chemotherapeutics against these
diseases would not be adequate in livestock, since they may generate unacceptable
residues in milk and meat that would avoid their commercialization. In this scenario,
prophylactic vaccines emerge as the most suitable approach. Subunit vaccines have
proven to be biologically safe and economically viable, allowing researchers to choose
among the best antigens against each pathogen. However, they are generally poorly
immunogenic and require the addition of adjuvant compounds to the vaccine formulation.
During the last decades, research involving plant immunomodulatory compounds has
become an important field of study based on their potential pharmaceutical applications.
Some plant molecules such as saponins, polysaccharides, lectins and heat shock
proteins are being explored as candidates for adjuvant/carriers formulations. Moreover,
plant-derived immune stimulatory compounds open the possibility to attain the main
goal in adjuvant research: a safe and non-toxic adjuvant capable of strongly boosting
and directing immune responses that could be incorporated into different vaccine
formulations, including mucosal vaccines. Here, we review the immunomodulatory
properties of several plant molecules and discuss their application and future perspective
as adjuvants in the development of vaccines against coccidial infections.
Keywords: coccidial parasites, plant-derived adjuvants, saponins, polysaccharides, lectins, heat shock proteins,
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INTRODUCTION
The phylum Apicomplexa is a large group of obligate intracellular protozoan parasites,
comprising more than 6,000 species (1), characterized by the presence of an assembly of
organelles called the apical complex (2) with some members being causative agents of the
most life-threatening infectious diseases of humans and other animals (3–6), even contributing
to increase human poverty (7, 8). In particular, among the most devastating Apicomplexan
parasites are those referred to as “coccidial parasites” such as Toxoplasma gondii, Cryptosporidium
parvum, Cyclospora cayetanensis, Neospora caninum, Eimeria spp., and Isospora spp. (9).
In fact, T. gondii; C. parvum, and other Cryptosporidium species are not only a major
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public health concern causing severe human disease (10–12), but
also cause significant economic damage to the livestock industry
(13–15). In the same way, parasites including N. caninum and
several species of the genus Eimeria and Isospora have been
reported to have an important negative impact on economic
animal production and animal welfare (16–22), leading to global
annual estimated losses in cattle industries exceeding US $1.300
million (16) and in poultry production industry in excess of US$
2 billion (22).
The outstanding ability of most coccidial parasites to
invade multiple vertebrate hosts and effectively manipulate
their immune responses, represent a huge challenge to most
currently available control strategies. Despite considerable efforts
have been made during the last decades to develop effective
prophylactic as well as therapeutic drugs and vaccines, there
has been only limited progress. Most of the drugs developed
against coccidial parasites are poorly effective or cause several
side effects (10, 11, 13, 23, 24) and when effective drugs have
been identified, as in the case of avian coccidiosis, resistance
frequently develops quickly (25, 26). Besides, there is an increased
public concern about the use of chemotherapeutics in livestock,
since they may generate unacceptable residues in milk and
meat that would avoid their commercialization and consumption
(27). Moreover, many anti-coccidial drugs are being banned
from use in food animals (26). Although prophylactic vaccines
emerge as the most suitable approach, successful vaccines against
coccidial parasites are scarce and limited to the veterinary
field (28). Most of them belong to one of the following
categories: live attenuated vaccines, killed vaccines or subunit
(and recombinant) vaccines. Currently, excluding one subunit
vaccine against chicken coccidiosis (Coxabic) [reviewed in (29)],
commercial vaccines against coccidial parasites are based on live
virulent or attenuated organisms and whole killed organisms
[reviewed in (26, 28)]. However, the safety of live vaccines is
questionable due to the risk of virulence reversion (30). In
contrast, recombinant subunit vaccines offer safer alternatives
(30) and may provide the best long-term sustainable solution.
However, purified antigens derived from different host systems
are often less antigenic and immunogenic than attenuated or
killed vaccine versions and the major challenge ahead is to devise
effective ways to deliver these antigens to the immune system
in order to stimulate appropriate immune responses (31, 32). In
this regard, it is widely accepted that subunit vaccines require
additional components to improve protective immunity. These
components are molecules, compounds, or macromolecular
complexes known as adjuvants (31). When incorporated into
a vaccine formulation, adjuvants are capable of enhancing the
magnitude of an adaptive response or modulating it toward
the desired immune response to produce the most effective
forms of immunity against each pathogen (31, 32). Despite
during the last decades several adjuvants have been assayed in
experimental subunit vaccines against coccidial parasites (11, 33),
none of them have demonstrated to effectively protect against
parasite infection, thus search for more appropriate and effective
adjuvants is still one of the main challenges in the development of
coccidial vaccines. Among the novel proposed adjuvants, plant-
derived molecules such as saponins, polysaccharides, lectins,
and heat shock proteins have proven to be potent immune
stimulatory compounds with low toxicity and side-effects (34,
35). In this review we will explore the most promising plant-
derived adjuvant molecules, and based upon their main immune
effects and proposed mechanism of action, we will discuss their
potential application in the development of new generation
vaccines against coccidial parasites.
ADJUVANTS: THE BLACK BOX OF
IMMUNOLOGY BEING OPENED
General Considerations
Vaccine adjuvants are used to improve the potency of the
immune response to co-administered antigens. Most adjuvants
are chemicals, molecules or particles obtained from infectious
agents or their derived toxins (e.g., FCA, monophosphoryl lipid
A, CT-B), mammalian proteins involved in “danger signals” and
even molecules or proteins from plants with immunomodulatory
properties (31, 34). Although adjuvant mechanisms of action
are still unclear, in the last 20 years significant progress has been
made to identify them. Three types of adjuvants are generally
recognized depending on their effector mechanisms: Type A
adjuvants (e.g., monophosphoryl lipid A, CpG ODN), which
are Pattern Recognition Receptor (PRR) agonists (36, 37); type
B adjuvants (e.g., Alum hydroxide, MF59, Freund’s adjuvant,
toxin-derived adjuvants, nanoparticles), which interact with
antigen presenting cells (APCs) and antigens in an unspecific
manner, which is the so-called depot effect, and associate with
the antigen to facilitate its transport to the lymph node (37, 38);
and, the less explored type C adjuvants, which are compounds
that interact with co-stimulatory molecules on APCs (e.g., CD28
superagonist antibody TGN1412) (37) (Figure 1). Recently, an
interesting approach arose to better understand the mechanisms
of action of adjuvants based on the search for their molecular
and cellular signatures (39–41). In this sense, genome-wide
transcript microarray analysis has demonstrated that CpG ODN,
an oligonucleotide previously characterized as a type A adjuvant,
can modulate an adaptive immune response and regulate a
large number of MF59 (type B adjuvant)-responsive genes,
suggesting that the effector mechanisms of adjuvants are far
from being completely elucidated (39) and must be evaluated in
vivo, in a more global way. Indeed, any classification of adjuvants
is difficult and may be incomplete, thus many of them resist
easy definitions.
Although the rational design of vaccines against each
pathogen has its own difficulties to overcome and represents
singular challenges, there are some common features that should
be taken into account in the selection of an adjuvant for the
development of vaccine formulations against coccidial parasites.
It is generally accepted that an appropriate immune response
against intracellular obligate protozoans is primarily dependent
on the cellular immunity mediated by both CD4+ and CD8+
T cells and their ability to secrete cytokines such as IFN-γ, as
in the case of T. gondii (42), Eimeria spp. (43), N. caninum
(33), Cryptosporidium spp. (44), and I. suis (21). These results
suggest that a candidate adjuvant for a potential anti-coccidial
vaccine should allow the correct processing and presentation
of antigen to the host immune system to stimulate proper
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FIGURE 1 | Classification of adjuvants. Type A adjuvants interact with pattern recognition receptors (such as Toll like receptors) and act as immune-potentiators of the
immune response (e.g., MPL). Type B adjuvants function as delivery systems by improving the recruitment of innate immune cells and favoring the Ag capture (e.g.,
Alum, MF59, CFA, IFA). Type C adjuvants are those compounds that act through co-stimulatory molecules (CD28) present in T cells (e.g., TGN1412).
cell mediated immune responses with reduced toxicity (26). In
addition, it would be highly recommended to deliver the vaccine
through the natural site of entry of most coccidial parasites,
the gut, so the development of an adjuvant that could be
orally/intranasally administered would also be desirable (32, 45).
In fact, among the various routes for application of vaccines,
mucosal immunizations depict many attractive features over the
parenteral routes, including lower risk of reactogenicity (32, 45).
However, most of the currently available mucosal vaccines (or
those in clinical trials) contain adjuvants that cause several side
effects [reviewed in (45)], which encourage the search for new
and safer mucosal adjuvants.
In the last decades, research involving plant
immunomodulatory compounds has become an important field
of study (34, 46). One of their most remarkable characteristics
rely on their capability of eliciting proper immune responses
with reduced toxicity (35, 46), and even some of them are able
to act as antigen carriers (35) or to deliver the antigens to M
cells in the Peyer’s Patch (47). Among the most promising plant
molecules and proteins for the development of adjuvants are
saponins, polysaccharides, lectins and heat shock proteins, thus
their properties and potential inclusion in anti-coccidial vaccines
will be discussed in the following sections.
Saponins and Saponin-Derived
Compounds
Saponins are natural steroidal or triterpene glycosides with
immune modulatory properties (48–52), widely distributed
in higher plants and usually found in roots, tubers, stems,
barks, leaves, blooms and seeds (53). Basically, their chemical
structures consist in non-polar aglycones linked to one or more
carbohydrate chains (Figure 2).
In general, plants produce saponins during their normal
development. However, Sparg et al. (53) suggested that saponins
are involved in plant defense mechanisms due to anti-microbial,
fungicidal and insecticidal activities. In addition, several plant
saponins are able to activate the mammalian immune system,
leading to significant interest in their potential as vaccine
adjuvants (Table 1). In fact, Quil A is a partially purified mixture
of saponins obtained from Quillaja saponaria and represents the
most widely used and studied saponin-based vaccine adjuvant
in mammals (37). Hence, Quil A and its purified form, saponin
QS-21, have long been used as adjuvants in veterinary vaccines
(82, 83). Quil A stimulates both humoral and cellular responses
against co-administered antigens, with the generation of Th1
and cytotoxic T lymphocytes (CTLs) responses (37). The ability
to elicit this type of immune response makes it ideal for use
in vaccines directed against intracellular pathogens, such as
coccidial parasites (48). In fact, Quil A has been administered
as a mucosal adjuvant against toxoplasmosis in subunit vaccines
including as antigens crude rhoptry proteins of T. gondii (58,
59, 64) or recombinant ROP2 (54, 60). These formulations
were evaluated in different host species, including cats (54, 58,
64), pigs (59) and mice (60), resulting in enhanced humoral
(58–60) and cellular immune responses (59) but, at best, in
partial protection against infection (59, 60, 64). In addition,
i.p. immunization against murine toxoplasmosis using another
recombinant antigen, T. gondii SAG3, resulted in increased
survival rate and decreased cysts formation, through induction
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FIGURE 2 | Molecular structure of Rg2 saponin from traditional Chinese
medicinal herbs with adjuvant activities.
of a Th1-type immune response (63). Quil A was also used in
an experimental vaccine against N. caninum, partially protecting
mice against cerebral infection when s.c. co-administered with
a N. caninum lysate (65). In a more recent research, Pastor-
Fernández et al. (55) showed that i.p. immunization with
different recombinant antigens from N. caninum (rNcROP4,
rNcROP2, rNcGRA7, and rNcNTPasa) as monovalent or pair-
wise combinations (rNcROP40 + rNcROP2 and rNcGRA7 +
rNcNTPase) + Quil A, increased specific immune responses,
decreased parasite burden in brain and partially protected
against vertical transmission in a pregnant mouse model of
congenital neosporosis.
In order to obtain a highly effective adjuvant, Quil A has
also been formulated as adjuvant complexes. Among them,
QCDC is composed by Quil A, cholesterol, dimethyl dioctadecyl
ammonium bromide (DDA), and Carbopol (84), whereas the
further incorporation of Bay R1005 [R], a synthetic glycolipid
analog, endows the complex with the ability to trigger both Th1-
and Th2-type immunity, giving the QCDCR adjuvant a broad
range of desirable immune enhancing characteristics (84). QCDC
has been evaluated as adjuvant in subunit recombinant vaccines
containing Profilin (rProfilin) against avian coccidiosis, both in
ovo immunization (61) and through the s.c. route in broiler
chickens (62), with contradictory outcomes, probably as a result
of the species of Eimeria used in each experimental infection (11)
(Table 1). The same antigen (rProfilin) was also formulated with
QCDCR and used in a s.c. immunization protocol in chickens,
that after experimental infection with E. acervulina showed
decreased intestinal lesions, increased body weight gain, and ex-
vivomitogen-induced lymphocyte proliferation (57). In addition,
the incorporation of CpG ODN[T] to QCDCR (QCDCR-T) was
able to increase the ratios CD4+/CD8+, TCR1+/TCR2+ and the
serum antibody titers against rProfilin in s.c. vaccinated and E.
acervulina challenged chickens (56).
On the other hand, saponins could also be formulated as
immune-stimulatory complexes (ISCOMs), which are particulate
antigen delivery systems composed of antigen, cholesterol,
phospholipids and Quil A (48) or ISCOMATRIXTM vaccines,
a similar formulation than ISCOMs but with much broader
application (85). Unlike most other adjuvants, ISCOMs are
able to elicit both CD8+ and CD4+ T cell responses in
mammals (36) and are approved for veterinary vaccines (36,
86). In fact, Pinitkiatisakul et al. (71) demonstrated that s.c.
immunization with recombinant protein SRS2 from N. caninum
(rNcSRS2) + ISCOMs diminished the clinical symptoms of the
disease in a mouse model of cerebral neosporosis. However, s.c.
immunizations with vaccine formulations containing ISCOMs as
adjuvants and native antigen extracts (67, 68) or the combination
of recombinant N. caninum proteins (66) in the target species,
Bos taurus, induced high titers of IgGs (66–68) and similar levels
of IFN-γ to those achieved after inoculation with live NC-1 (68),
but failed to prevent vertical transmission (66, 67). Similarly,
examples of ISCOMs vaccine formulations are found against T.
gondii infection in s.c. immunization protocols in pigs using as
antigens total native antigens fromT. gondii (73) or crude ropthry
proteins (72), also depicting high humoral (72, 73) and cellular
immune responses (73) but only partial protection against
infection (87). Finally, these immunostimulatory complexes
were also included in immunization protocols against avian
coccidiosis. Just to name a few, early studies from Kazanji
et al. (74) demonstrated that a native surface sporozoite
protein purified from E. falciformis (AgP27) incorporated in
ISCOMs induced the secretion of high levels of serum IgG,
local IgA, enhanced the cellular immune response, triggered
antigen-stimulated ex-vivo proliferation of T-lymphocytes and
conferred partial protection in an orally immunized mice
model of coccidiosis. Later, García et al. (70) showed that a
similar formulation (ISCOMs + native sporozoites from E.
tenella) diminished the intestinal lesions score and the oocyst
shedding in E. tenella infected broiler chicken. In a more recent
work, Berezin et al. (69) showed that i.n. immunized broiler
chickens with formulations of ISCOMs containing purified
saponins derived from native plants from Kazakhstan and E.
tenella antigens, achieved significant immunostimulation and
protection against challenge.
Although saponins obtained from Quillaja saponaria, such
as Quil A and QS-21 and their derivative compounds, have
proven adjuvant potential, their high toxicity and undesirable
hemolytic effects have restricted their use in human vaccination
(48). Therefore, considerable efforts have been made to discover
new plant saponins with high adjuvant activity and reduced
toxicity (48, 82, 83, 88, 89). Among them, saponins present in
the leaves of Quillaja brasiliensis, especially a saponin fraction
named QB-90, with remarkable structural similarities to Quil
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A, showed lower toxicity when subcutaneously administered to
mice (88). In addition, QB-90 strongly potentiated the immune
response to a viral antigen (bovine herpes virus type 1, BoHV-
1), indicating that QB-90 is a safe and strong vaccine adjuvant
(88). Many other alternative sources of saponins with immune-
stimulatory properties and low toxicities include: saponins from
the roots from Panax notoginseng (90), saponin fractions Rg1 and
Rb1 from the root of Panax ginseng (91, 92), total saponins from
stems and leaves of P. ginseng (87, 93), saponins from Platycodon
grandiflorum (PGS) (94) and saponins from the roots of Pulsatilla
chinensis (PCS) (89).
Up to now, the adjuvant activity of saponins has been related
to its structure, which is comprised of hydrophilic sugar side
chains and a hydrophobic aglycone back-bone (48). Nakaya
et al. (95) suggested that the activity of adjuvant saponins
would be initiated when saponins bind and activate specific
receptors on APCs. In particular, ginseng extract stimulates the
production of proinflammatory cytokines in macrophages via
TLR4 (95). In addition, Bangham et al. (96) showed that Quil
A is able to intercalate into cell membranes forming pores. This
mechanism allows the antigen access to the antigen endogenous
presentation pathway (96). However, it is unknown if those
molecularmechanisms are common tomost saponins. In the case
of ISCOMS and ISCOMATRIXTM vaccines, they act as delivery
system for most antigens, and their mechanism of action is
very complex and combine antigen presentation by both MHCI
and MHCII pathways, interaction with APC, stimulation of T
helper subset, activation of CTLs and a broad immune response
that depends on the induction of multiple immune mediators,
which were extensively reviewed by Sun et al. (48). In this
context, further investigation should be carried out to determine
the possible modes of action exerted by saponins and their
derivative compounds.
Polysaccharides
Many polysaccharides from plants, and particularly, those
derived from Chinese medicinal herbs, have emerged as excellent
candidates to replace traditional adjuvants, since they can
stimulate the immune system, are less toxic and have fewer
collateral effects than bacterial polysaccharides and synthetic
compounds (97) (Table 1). The common structural moiety of
many bioactive polysaccharides from plants are basically, β-(1→
6)-branched β-(1 → 3) gluco-oligosaccharides. Thus, the basic
unit of β-glucan would have the immunostimulatory effects of the
whole polysaccharide (98) (Figure 3).
In particular, polysaccharides from Astragalus membranaceus
(AMPS) have shown important adjuvant capacity when added
to vaccines against foot-and-mouth disease virus, infectious
bursal virus, avian influenza virus and avian infectious bronchitis
virus (IBV) [reviewed in (97)], demonstrating its potential for
the development of vaccine formulations against intracellular
pathogens such as Coccidia members. Indeed, a water-soluble
polysaccharides extract from A. membranaceus have shown
promising results against an experimental E. tenella infection in
broiler chickens when fed with the extract as diet supplement
and immunized with a live attenuated E. tenella vaccine (75).
Moreover, Yang et al. (76) have shown that mice i.p. vaccinated
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FIGURE 3 | Common structural moiety of many bioactive polysaccharides.
with UV-attenuated T. gondii parasites co-administrated with
water soluble extract of A. membranaceus exhibited longer
survival rate, lower parasite burden, lower liver histopathological
score, and higher Th1 response after challenge.
A new soy-lecithin adjuvant, Providean-AVEC R©, was used
by Mansilla et al. (77) in the development of a vaccine against
neosporosis. This adjuvant, which contains β-glucans from barley
and yeast and a soluble extract from Chenopodium quinoa whole
seeds, has demonstrated to completely limit the multiplication
of the parasite causing the pathogenesis, to activate DCs and
to enhance cellular responses when formulated with soluble
N. caninum antigens (SNcAg) and s.c. administered to mice
(77), encouraging its use against this parasite. In a follow-
up study, Mansilla et al. (78) demonstrated that the vaccine
formulation containing Providean-AVEC R© + SNcAg stimulated
broad cellular and humoral immune responses against N.
caninum in cattle. However, their effect on vertical transmission
in heifers was not evaluated; thus, conclusions about vaccine
efficacy were not conclusive.
To our knowledge, no other plant-derived polysaccharide has
been used in vaccine formulations against coccidial parasites,
despite their proven adjuvant potential (97). In fact, AdvaxTM
is undoubtedly one of the most promising adjuvants obtained
from plant sources, since it has been approved for human
clinical trials (99, 100). Indeed, in a Phase 1/2 study in adult
subjects, AdvaxTM adjuvant enhanced the immunogenicity of a
recombinant hemagglutinin vaccine against pandemic influenza
A/H1N1/2009 by increasing seroprotection rates with no
adjuvant-associated adverse reactions observed (99). In addition,
it also increased anti-Hepatitis B antigens (HBsAg) antibody
titers and seroprotection rates when compared to administration
of HBsAg alone in healthy human adults (100). AdvaxTM has also
proven to successfully enhance vaccine immunogenicity across
a broad range of antigen types and animal species tested so
far, regardless of immunization routes, even when given during
pregnancy or in early neonatal life [reviewed in (101)]. Hence,
AdvaxTM arise as a candidate adjuvant for coccidial vaccines
based upon its ability to stimulate both, CD8+ and CD4+ cell
proliferation as well as Th1/Th2 cytokine response (102) and the
characteristics mentioned above.
Among other plant polysaccharides with potential
immunostimulatory properties is a water-soluble polysaccharide
extracted from the roots of Actinidia eriantha (AEPS), a
plant generally used in traditional Asian medicine (98). AEPS
demonstrated to be a potent adjuvant for OVA-specific cellular
and humoral immune responses, elicited a balanced Th1/Th2
immune profile in mice and caused neither mortality nor side
effects when it was subcutaneously administered (98).
Finally, polysaccharides from the root of Angelica sinensis
(ASPS), a well-known Chinese herbal medicine, have attracted
much attention, since many studies have demonstrated
that they have various bioactivities, such as hematopoiesis,
immunomodulation, anti-oxidant and anti-tumoral effects
[reviewed in (103)]. Besides, when incorporated as adjuvant in
a Newcastle disease virus vaccine, it increased antibody titers,
achieving better immune results than the vaccine alone (104).
All these examples show that plant polysaccharides are
able to enhance specific responses against the antigen when
administered parenterally. Also, plant polysaccharides have
intrinsic muco-adhesive properties that may improve the
interaction of the mucosa membrane with luminal antigen
and facilitate its uptake, supporting the idea that plant
polysaccharides can be used as oral adjuvants (105, 106). In
this sense, Lemnan LM, apiogalacturonanic pectin of duckweed
Lemna minor, was found to stimulate phagocytes and therefore
tested, in the murine model, for adjuvant properties by oral
administration withOVAprotein antigen (105). Interestingly, the
oral administration of the mixture of OVA and Lemnan achieved
substantial systemic and local mucosal immune responses.
Hence, Lemnan appears to elicit adjuvant activity via induction
of both Th1 and Th2 responses (105). On the other hand, in mice,
oral administration of poly phenylpropanoid-polysaccharide-
rich extract of pine cones (PPC) suppresses the generation of IgE
and enhances the generation of a Th1 cellular immune response
(106), supporting the hypothesis that PPC could be used as
oral adjuvant.
Although the mechanism of action of most plant
polysaccharides remains elusive, it has been proposed that
adjuvant activity starts with the binding to specific carbohydrate
receptors expressed on APCs (107). In particular, macrophages
might be activated by polysaccharides via TLR4, CD14,
complement receptor 3 (CR3; also known as CD11b/CD18),
scavenger receptors, dectin-1 and mannose receptor (108). The
activation of these receptors leads to intracellular signaling
cascades, resulting in transcriptional activation, monocyte
maturation and the production of pro-inflammatory cytokines.
In addition, activation of macrophages by polysaccharides can
occur via an endocytosis-dependent pathway. Polysaccharides
would become endocytosed after associating with macrophage
receptors (101).
Lectins
Lectins exist in almost all living organisms and are carbohydrate-
binding proteins which function as receptors to various cell
surface glycoproteins, resulting in several important cell-
mediated events, ranging from mitogenic processes to plant
defense mechanisms (109, 110). In particular, plant lectins
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FIGURE 4 | Homotetrameric assembly of Lectin UEA-II from Ulex europaeus
(10.2210/pdb1dzq/pdb). This assembly was defined by Loris et al. (112). The
crystal structure was determined using X-ray diffraction at a resolution of 2.85
Å and downloaded from the protein data bank: http://www.rcsb.org/.
represent a biochemically and structurally varied group [for
details see (111)], which probably reflects a certain degree of
functional diversity (34). The main conformational component
of most plant lectins is the β-sheet. Three main kinds of β-sheet
architectures are found in plant lectins: the barrel, hevein domain
and the jelly roll (or legume lectin fold) (110). The structure of a
typical plant lectin is shown in Figure 4.
Plant lectins were first identified as proteins capable of
agglutinating blood cells, and concanavalin A (ConA) from
jack bean (Canavalia ensiformis) seeds was the first to be
isolated almost a century ago (113). Several plant lectins
showed immunomodulatory effects that are stimulated by their
interaction with glycan’s moieties present on the surface of
immune cells (114). As a result of this interaction, signal
transduction mechanisms are triggered to produce cytokines.
Many plant lectins induce Th1 immunity [widely reviewed in
(114)], manifested by high levels of IFN-γ production whereas
a few stimulate Th2 immunity, as in the case of Synadenium
carinatum latex lectin (ScLL) (115), leading to immune responses
that could be beneficial against different pathogens and tumors.
The immunomodulatory properties of plant lectins have
encouraged their screening for potential pharmaceutical
applications, among them, the development of adjuvants.
An important characteristic of certain plant lectins rely on
their ability to interact with the mucosal epithelium and
to be translocated across the gut, which may be exploited
in vaccine formulations to induce mucosal and systemic
immunity (47, 86) In the last few years, lectins from the
jackfruit (Artocarpus integrifolia), ArtinM and Jacalin (JAC)
have arisen as potential adjuvants in vaccines against protozoan
parasites (80, 81, 116–119). In particular, ArtinM, stimulates
macrophages and dendritic cells to produce IL-12 (120), through
ArtinM interaction with the N-glycans of TLR2 (121), inducing
a biased Th1-immune response. In fact, administration of
ArtinM alone or in combination with soluble Leishmania major
antigens (SLA) partially protects immunized mice against L.
major (120) or L. amazonensis infection (116). The murine
models of Leishmaniasis provide strong evidence for the
immunomodulatory effect of ArtinM toward a Th1 profile
through the modulation of IL-12 secretion. The beneficial
effects of this lectin against Leishmania spp. have encouraged
its evaluation as adjuvant/chemotherapeutic drug against
coccidial parasites (Table 1). In fact, Cardoso et al. (81) have
demonstrated that s.c. administration of ArtinM + Neospora
lysate antigens (NLA) increased IgG and IgG2a/IgG1 ratio and
partially protected mice from N. caninum infection. On the
other hand, despite Jacalin, the major protein from Artocarpus
integrifolia seeds, has demonstrated to act as a potent adjuvant
when administered in combination with epimastigotes from
Trypanosoma cruzi (117), only mild effects were obtained when
s.c. administered to mice in combination with NLA against N.
caninum (81).
Another plant lectin recently isolated and characterized
by Souza et al. (122), a D-galactose-binding lectin named
Synadenium carinatum latex lectin (ScLL), showed
immunostimulatory, immunoprotective and adjuvant effects in
a mouse model of cerebral neosporosis when administered with
NLA, resulting in increased IgGs production, higher survival rate
and decreased parasite burden (80) (Table 1). Peixoto Ferreira de
Souza et al. (79) offered a different approach, and observed that
i.p. treatment of mice with ScLL or ScLL + ArtinM previously
infected with T. gondii significantly decreased parasite burden
and increased survival rates, demonstrating the potential of
ScLL and ArtinM lectins as immunotherapeutic agents against
acute toxoplasmosis.
Although several plant lectins gathered the main
characteristics of a potential adjuvant candidate to be used
in vaccines against coccidial infections, most of them have
not been evaluated in immunization protocols against these
parasites yet. Among them, one of the best characterized is
the B subunit of ricin toxin (RB) of the Ricinus comunis,
which has been used as adjuvant/carrier protein fused to a
reporter antigen (123), as well as to the simian rotavirus SA-
11 non-structural protein NSP4 (124) in orally immunized
mice, resulting in the secretion of IgG1 and IgG2 anti-GFP
antibodies (123) or enhancement of Th1 immune response
(124). Several other lectins, including lectins from Viscum album
(mistletoe lectin 1; ML-1), Lycopersicum esculentum (tomato
lectin; LEA), Phaseolus vulgaris (PHA), Triticum vulgaris (wheat
germagglutinin (WGA), and Ulex europaeus (UEA-1) when
evaluated as adjuvants in immunization protocols in mice,
have demonstrated to stimulate the production of specific
anti-bystander antigen (OVA) antibodies (serum IgG and
IgA) (47). In particular, UEA-1 has proven to specifically bind
to M cells from the Peyer’s patches resulting in an excellent
candidate for microencapsulation strategies (34). In fact,
Manocha et al. (125) have demonstrated that i.n. immunization
of mice with HIV peptides entrapped in polylactide-coglycolic
acid microparticles in combination with UEA-I enhanced
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FIGURE 5 | Scheme of the domain structure of yeast Hsp90 (A) and E. coli Hsp70 (B), defined by limited proteolysis and structural studies. Hsp90s have an
N-terminal peptide binding domain (N), a middle segment (M) that interacts with client proteins and contributes with ATP hydrolysis, and a C-terminal domain (C),
involved in homodimerization. Hsp70s consist of an N-terminal ATPase domain (N) followed by a substrate binding domain (S) and a C-terminal domain (C), which
forms a lid-like structure over the substrate-binding pocket that helps trap substrates in the substrate binding domain.
systemic and mucosal immune response. In addition, vaccine
formulations containing killed whole Helicobacter pylori or
Campylobacter jejuni conjugated to UEA-1 induced protective
immune responses against live challenge in orally immunized
mice (126).
Regarding the mechanism of actions of plant lectins, it has
been shown that some of these lectins are able to interact with
glycosylated TLR receptors on macrophages and/or DCs. In fact,
several plant lectins might act as TLR agonists (118). The soybean
(SBA), peanut agglutinin (PNA), ConA, and PHA lectins (PHA-
L) are able to stimulate extracellular TLRs (118). In particular,
Souza et al. (114), showed that ArtinM recognizes TLR2 N-
glycans, but not TLR4 N-glycans. In addition, the production
of IL-12 by macrophages under ArtinM stimulation requires the
MyD88 adaptor molecule (114).
Heat Shock Proteins
Heat shock proteins (Hsps) are molecular chaperones essential
for preventing inappropriate associations or aggregations of
partially folded proteins (127). They are highly conserved
among eubacteria, yeasts, plants and animals (127). According
to their molecular weights and degree of identity, Hsps are
grouped in Hsp110, Hsp90, Hsp70, Hsp60, Hsp40, and small
Hsps (128). Hsp90 has three structural domains: an N-terminal
nucleotide binding domain that also binds Hsp90 inhibitors
and may bind peptides; a middle segment that interacts with
client proteins; and the C- terminus, which is involved in
homodimerization (Figure 5A). In contrast, Hsp70 has two
domains: an N-terminal nucleotide binding domain and a
substrate binding domain (Figure 5B). For these two proteins,
the structural basis of peptide binding and dynamic models
of ligand interaction is notably understood, but how the
basic biology of Hsps influences their immunological functions
remains uncertain.
Early studies showed that Hsp70 or Hsp90 peptides
complexes purified from different types of cancers were
able to produce specific anti-tumor immunity (129, 130). Later,
several researchers found that Hsps were able to bind antigenic
peptides (131), facilitating antigen presentation by the Major
histocompatibility complex class I (MHC I) (132), resulting in
activation of CD8+ T cells (133, 134). The combined properties
of Hsps to drive innate stimulation and deliver antigens to the
APCs represent a link between innate and adaptative immune
responses, thus, their natural adjuvant capacity is now being
exploited in prophylactic vaccines against infectious diseases.
In particular, Hsp complex (HSPC) vaccines are based on the
enrichment of Hsps from bacteria along with its bound protein
cargo and can potentially produce an effective vaccine without
requiring the addition of an exogenous adjuvant, as it has been
demonstrated for a tuberculosis vaccine based on HSPC from
BCG (T-BioVax) in mice (135) and a vaccine against meningitis
(MenBioVax) derived from heat-shocked protein-antigen
complex against Neisseria meningitidis in humans (136). Other
vaccine approaches include the administration of Hsps derived
from several organisms mixed, complexed or fused to many
different antigens and evaluated as adjuvants/carriers. In fact,
several examples of recombinant Hsps from bacteria or human
sources covalently linked to viral or protozoan antigens have
demonstrated to enhance both humoral and cellular immune
responses in murine models (137–139). Similar results were
observed using L. infantum Hsp70 (LiHsp70) fused to maltose
binding protein (MBP) as reporter antigen and evaluated in
mice (140). Later, LiHsp83 was fused to T. gondii recombinant
Rop2, and used as adjuvant-free vaccine formulation (foot-
pad injection) in mice, causing predominance of specific
IgG2a/IgG2c isotype and IFN-γ secretion, which in turn,
conferred a remarkable resistance against toxoplasmosis (141).
In addition, recent results from our laboratory demonstrated
that LiHsp83 fused to T. gondii SAG1 and expressed in tobacco
plants not only stimulated the production of specific anti-SAG1
IgGs and partially protected orally vaccinated mice from T.gondii
infection, but also increased the level of T. gondii antigen
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accumulation in leaves (142). In fact, the ability of Hsps to
chaperone peptides could provide stability to recombinant
proteins, increasing the production yields and providing added
value to plant based platforms, suggesting that Hsps could be
used as novel carriers/adjuvants for vaccine antigen candidates
to improve immunogenicity of recombinant antigens produced
in plants.
These results suggest that several Hsps and not just those
from the same species could be used as adjuvants/carriers
in vaccine development against different pathogens that
require a Th1 response to confer immunity. Although the
immunological properties of Hsp70 and Hsp90 from humans
and other organisms as bacteria and apicomplexan parasites
are also present in their plant orthologs (35, 143, 144), the
carrier/adjuvant properties of plant Hsps are less explored, even
considering the advantage that plant Hsps are not derived from
human pathogens. However, Buriani et al. (35) demonstrated
that the structure of plant-derived Hsp70 (pHsp70) can be
superimposed to the mammalian homolog and that, similarly
to the mammalian counterpart, pHsp70–polypeptide complexes
can activate the immune system. The same authors showed
that pHsp70 purified from plant tissues transiently expressing
the influenza A virus nucleoprotein is able to induce both
the activation of MHC class I restricted polyclonal T-cell
responses and antibody production in different mouse strains
without the need of exogenous adjuvant (143). Similarly,
in a recent report of our laboratory, Corigliano et al. (144)
showed that in vitro incubation of splenocytes from naïve
mice with recombinant plant Hsp90 (rpHsp90) elicited the
expansion of CD19+ population. These results were supported
by immunofluorescence analysis suggesting a direct effect of
rpHsp90 on B cell proliferation. In the same study, it was
demonstrated that stimulation of splenocytes with rpHsp90 was
TLR-4 dependent since a low proliferation of spleen cells from
C3H/HeJ mice, which have a point mutation in the cytoplasmic
region of the TLR4 receptor, was detected. In a more recent
study, Corigliano et al. (145) showed that i.p. immunization
of mice with a fusion protein composed by pHsp90s and a
reporter antigen induced a strong Th1 response along with a
CD8+ cytotoxic cell response conferring immunity against the
reporter antigen.
Taken together, these data imply that plant Hsps combine
various advantageous properties, such as the capacity to bind
antigenic peptides, deliver them to APC, exert immune-
stimulatory effects, enhance strong Th1 response, and in the case
of plant-based vaccines, results based on LiHsp83 suggest that
pHsps probably should increase antigen accumulation in vegetal
tissue, encouraging their use as carrier/adjuvants in vaccine
formulations against coccidial infections, both in mucosal and
parenteral immunizations.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
Undoubtedly, coccidial infections are a major public health
concern, also responsible for some of the most important
veterinary diseases, leading to important economic losses in
poultry and cattle industries. Although prophylactic vaccines
emerge as the best approach to control coccidial parasites,
the currently available vaccines are mostly based on live
parasites, depicting serious issues related to vaccine safety.
Despite subunit vaccines are a safer and more sustainable option,
there is a reason why veterinary (or medical) medicine has
not developed recombinant antigen vaccines for the prevention
of every coccidial infections: they have not been effective
enough to protect immunized individuals. This statement
does not imply that such vaccines will never attain better
results, since the application of omics -technologies during
the last decades has improved our knowledge of effective
immune responses in the hosts, as well as, the molecular
basis in the host cell-parasite interaction, which provides
important information that can be exploited for the rationale of
vaccines design, including the selection of the most appropriate
adjuvant. However, this is not an easy task. Although it is
generally accepted that a proper adjuvant for vaccines against
coccidial infections should allow the antigen processing and its
presentation to the host immune system to enhance a strong
cellular immune response, with IFN-γ secretion and reduced
toxicity, each parasite has its own strategies to invade the
host species, multiply, and escape the immune system, which
represents singular challenges to overcome in the development
of vaccine formulations.
Plant derived-adjuvants have, at least, two remarkable
properties: first, most of them are relatively non-toxic and
do not cause significant side effects, which are a major
concern associated with synthetic compounds and second,
they have proven to potentiate the immune response even
when administered orally, making attractive the use of these
compounds for the development of mucosal vaccines. In
fact, some saponin-derived adjuvants, such as Quil A, are
currently used in veterinary vaccines. Indeed, Quil A has
demonstrated to improve immune protection when formulated
in anti-coccidial vaccines through a Th1-biased immune
response. In addition, ISCOMs have been widely used in
experimental vaccines against Eimeria spp., T. gondii, and
N. caninum with promising results, which turn them into
clear candidates to be tested in vaccination trials in the next
few years. As detailed above, certain plant polysaccharide
extracts have been used in experimental live vaccines or in
immunization protocols containing native antigens from
coccidial parasites confirming their adjuvant properties.
However, up to now, the most attractive adjuvant derived
from plant polysaccharides is AdvaxTM, used in human
influenza pandemic vaccine, which has demonstrated to be
highly immunogenic and safe which encourages its use in the
development of vaccine formulations against coccidial diseases.
In addition, lectins and their derivative biodegradable polymers
show immunomodulatory activities and extensive animal
studies demonstrate their safety. In particular, ArtinM and
ScLL not only are potent adjuvants in immunization protocols,
but also have proven to be potential chemotherapeutic drugs
against T. gondii. More recently, plant heat shock proteins
Hsp70 and Hsp90 demonstrated to enhance both humoral and
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cellular immune responses, with a clear Th1-biased profile
and CD8+ T cells activation, arising as novel non-pathogenic
adjuvant/carrier candidates.
Data here reviewed suggest that plant-derived adjuvants open
the possibility to attain the main goal in adjuvant research:
a safe and non-toxic adjuvant capable of strongly boosting
and directing immune responses that could be incorporated
into different vaccine formulations against coccidial diseases.
However, it is difficult to decide which adjuvant represent the
best option to be included in immunization protocols, since the
lack of well-defined infection models for each coccidial parasite
has rendered the comparison of results obtained in different
reports a difficult undertaking. A challenge ahead is to establish
harmonized animalmodels thatmimic the infections of the target
species to be used in immunization protocols, as well as, to define
which parameters have to be evaluated in order to properly asses
vaccine efficacy.
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